Current Opinion in Urology

Skip Navigation LinksHome > May 2009 - Volume 19 - Issue 3 > Novel secondary hormonal therapy in advanced prostate cancer...
Current Opinion in Urology:
doi: 10.1097/MOU.0b013e328329b73a
Prostate cancer: Edited by Andrew Stephenson

Novel secondary hormonal therapy in advanced prostate cancer: an update

Van Allen, Eliezer M; Ryan, Charles J

Collapse Box


Purpose of review: In a large proportion of advanced prostate cancer patients treated with androgen deprivation therapy, progression of the disease occurs despite low levels of testosterone, termed castration-resistant prostate cancer. This heralds the onset of the lethal form of the disease. Recent investigations into the mechanisms of castration resistance have shown that despite low levels of androgen, the androgen receptor remains active through a variety of mechanisms and thus represents a key treatment target in castration-resistant prostate cancer.

Recent findings: Clinical approaches to these patients have rapidly progressed and include antiandrogen withdrawal, sequential antiandrogen use, adrenal androgen production inhibitors, and estrogenic compounds. Multiple efforts are underway to develop additional therapies targeted at this phenomenon.

Summary: Hormonal therapy in advanced prostate cancer is rapidly evolving to more effectively target disease processes underlying prostate cancer, with multiple promising agents on the horizon.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.